Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWX205 SAD Study in Adult Participants With Dyslipidemia
NCT07634510Phase 1Not yet recruiting
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Oct 2026
01
Overview
Phase 1, randomised, double-blind trial in dyslipidemia comparing MWX205 with Placebo (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Incidence of Serious Adverse Events and 3 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
MWX205
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT07634510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07634510.